MannKind Corporation: Q3 2011 Form 10-Q Summary
Business Context and Reporting Period
MannKind is a development-stage biopharmaceutical company focused on diabetes and cancer therapies. Its lead candidate, AFREZZA inhaled insulin, remained in late-stage development and had not received FDA approval or generated product sales. The filing covers the three and nine months ended September 30, 2011, compared with the corresponding 2010 periods.
Key Financial Metrics
| Metric | Q3 2011 | Q3 2010 | 9M 2011 | 9M 2010 |
|---|---|---|---|---|
| Revenue | $0.0 million | $0.0 million | $0.05 million | $0.09 million |
| Research and development expense | $23.1 million | $31.4 million | $79.7 million | $88.1 million |
| General and administrative expense | $9.6 million | $11.1 million | $30.3 million | $32.4 million |
| Operating loss | $32.8 million | $42.5 million | $110.0 million | $120.4 million |
| Net loss | $38.4 million | $45.3 million | $124.4 million | $132.3 million |
| Basic and diluted loss per share | $0.31 | $0.40 | $1.02 | $1.17 |
| Net cash used in operating activities | Not provided for the quarter | Not provided for the quarter | $103.5 million | $109.7 million |
Gross profit and operating margins are not meaningful because the company had no product revenue and is not commercialized. The company reported cumulative net losses of approximately $1.9 billion and cumulative negative operating cash flow of approximately $1.5 billion since inception.
At September 30, 2011, cash and cash equivalents were $22.8 million, marketable securities were $0.5 million, and total liquidity was approximately $23.3 million. Property and equipment was $196.4 million. Stockholders’ deficit was $280.8 million.
Debt consisted primarily of $210.3 million in senior convertible notes and $277.2 million owed under the related-party loan arrangement with The Mann Group, for total reported debt of approximately $487.5 million before considering other liabilities. The related-party facility had $45.0 million of remaining availability and a December 31, 2012 maturity date.
Material Changes Versus the Prior Comparable Period
- Q3 net loss declined by $6.9 million, or approximately 15%, from $45.3 million to $38.4 million; nine-month net loss declined by $7.8 million, or approximately 6%.
- Research and development expense declined 26% in Q3 and 9% for the nine-month period, primarily because of lower raw-material, salary, and stock-based compensation costs following the February 2011 restructuring.
- General and administrative expense declined 13% in Q3 and 7% for the nine-month period.
- Interest expense increased by approximately $1.0 million in Q3 and $4.2 million for the nine-month period, reflecting the 2010 issuance of the 5.75% convertible notes and additional related-party borrowings.
- Operating cash use improved by $6.2 million year over year for the nine-month period, but remained substantial at $103.5 million.
- The company reduced its workforce by approximately 41% to 257 employees. It recorded approximately $6.4 million of restructuring costs during the first nine months, with approximately $0.4 million remaining accrued at September 30.
- The company completed a $16.0 million settlement with Organon related to termination of an insulin supply agreement. During the nine months, it recorded $8.4 million for insulin received and $7.6 million as a contract cancellation fee.
- The Seaside equity purchase agreement and the related Mann Group stock purchase agreement terminated during Q3. Cumulative proceeds from Seaside totaled $23.8 million, while 3.5 million shares issued to The Mann Group reduced related-party debt by $27.8 million.
Outlook, Management Commentary, Risks and Unusual Items
- The FDA issued a second Complete Response letter in January 2011, requiring additional clinical studies using the next-generation inhaler and additional information on safety, device performance, handling, storage, training, and labeling.
- Following discussions with the FDA in August 2011, MannKind confirmed the design of two additional Phase 3 studies in type 1 and type 2 diabetes. Subject to timely enrollment, management expected to complete both studies during 2012 and submit results as an NDA amendment by the first half of 2013.
- Management expected 2011 research and development expense to be slightly below the prior year, with restructuring savings partly offset by costs of the additional FDA-required trials. General and administrative expense was expected to be generally consistent with the prior year.
- The company expected existing capital resources, including the remaining related-party borrowing capacity, to fund planned operations only into the first quarter of 2012. Management stated that substantial additional financing would be required and that failure to obtain it would create substantial doubt about the company’s ability to continue as a going concern.
- On September 23, 2011, the company announced a proposed offering of senior secured discount notes due 2017 expected to generate approximately $370.0 million gross proceeds, subject to market conditions. The filing does not establish that the offering was completed.
- Potential funding sources included equity or debt issuance, strategic collaboration, licensing, asset sales, additional related-party borrowing, or other financing arrangements. These alternatives could dilute existing stockholders, increase leverage, restrict operations, or be unavailable on acceptable terms.
- The company had securities class actions, shareholder derivative actions, and an employment-related arbitration pending. The company had not accrued liabilities for these matters; the potential loss from the shareholder litigation could not be estimated.
- Major risks included failure to obtain FDA approval, unsuccessful or delayed clinical trials, manufacturing and supply constraints, lack of a commercialization partner, competition, intellectual-property disputes, product liability, litigation costs, and dependence on the company’s principal stockholder and related-party financing.
Most Important Facts for Investors to Verify
- Whether the proposed $370.0 million senior secured note offering was completed after the filing date and on what terms.
- Actual cash use, financing activity, and available related-party borrowing capacity following September 30, 2011.
- Status, enrollment, results, and FDA acceptance of the two additional AFREZZA Phase 3 studies and the targeted 2013 NDA amendment.
- Whether AFREZZA ultimately obtained regulatory approval and achieved commercial sales; this filing reports no product revenue.
- Current maturity, conversion, collateral, and refinancing requirements for the 2013 and 2015 senior convertible notes and the related-party loan.
- Subsequent developments in the securities class actions, derivative lawsuits, employment arbitration, and any related financial exposure.